- Home
- MDB vs ALNY Comparison
MDB vs ALNY Comparison
Compare MDB & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDB | ALNY |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8B | 34.2B |
| IPO Year | 2017 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MDB | ALNY |
|---|---|---|
| Price | $336.54 | $234.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 40 | 30 |
| Target Price | ★ $449.74 | $368.71 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 11-30-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 49.13 | ★ 206.88 |
| EPS | 0.55 | ★ 2.71 |
| Revenue | N/A | ★ $1,037,418,000.00 |
| Revenue This Year | $22.80 | $47.52 |
| Revenue Next Year | $19.05 | $25.98 |
| P/E Ratio | $667.22 | ★ $86.34 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $215.68 | $197.81 |
| 52 Week High | $473.10 | $495.55 |
Technical Indicators
Market Signals| Indicator | MDB | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 48.64 |
| Support Level | $322.07 | $219.54 |
| Resistance Level | $362.27 | $244.03 |
| Average True Range (ATR) | 18.76 | 8.43 |
| MACD | -1.17 | 0.23 |
| Stochastic Oscillator | 18.48 | 45.05 |
Price Performance
Historical ComparisonAbout MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates the development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.